MX2022006732A - Conjugados peptidicos y metodos de uso. - Google Patents

Conjugados peptidicos y metodos de uso.

Info

Publication number
MX2022006732A
MX2022006732A MX2022006732A MX2022006732A MX2022006732A MX 2022006732 A MX2022006732 A MX 2022006732A MX 2022006732 A MX2022006732 A MX 2022006732A MX 2022006732 A MX2022006732 A MX 2022006732A MX 2022006732 A MX2022006732 A MX 2022006732A
Authority
MX
Mexico
Prior art keywords
peptide
receptor
modulates
peptide conjugates
glp
Prior art date
Application number
MX2022006732A
Other languages
English (en)
Inventor
Weijun Shen
Elsa Pflimlin
Sam Lear
Zaid Amso
Peter G Schultz
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2022006732A publication Critical patent/MX2022006732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se divulgan en la presente conjugados peptídicos que comprenden un péptido seleccionado de un péptido que modula el receptor del PYY, un péptido que modula tanto el receptor del GLP-1 como el receptor del GCG, un péptido que modula tanto el receptor del GLP-1 como el receptor del GIP, y un péptido que modula el receptor del GLP-1; y una estructura tipo grapa unida al péptido en un primer aminoácido y en un segundo aminoácido. También se proporcionan conjugados peptídicos que comprenden el péptido liberador de prolactina. Los conjugados peptídicos pueden utilizarse para tratar afecciones tales como la obesidad. Además se proporcionan péptidos liberadores de prolactina engrapados.
MX2022006732A 2019-12-04 2020-12-03 Conjugados peptidicos y metodos de uso. MX2022006732A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943667P 2019-12-04 2019-12-04
US202062994791P 2020-03-25 2020-03-25
PCT/US2020/063149 WO2021113535A1 (en) 2019-12-04 2020-12-03 Peptide conjugates and methods of use

Publications (1)

Publication Number Publication Date
MX2022006732A true MX2022006732A (es) 2022-08-19

Family

ID=76222285

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022006861A MX2022006861A (es) 2019-12-04 2020-12-03 Agonistas del receptor glp2 y metodos de uso.
MX2022006732A MX2022006732A (es) 2019-12-04 2020-12-03 Conjugados peptidicos y metodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022006861A MX2022006861A (es) 2019-12-04 2020-12-03 Agonistas del receptor glp2 y metodos de uso.

Country Status (10)

Country Link
US (2) US20230057847A1 (es)
EP (2) EP4069274A4 (es)
JP (2) JP2023513658A (es)
KR (2) KR20220123648A (es)
CN (2) CN115052886A (es)
AU (2) AU2020397917A1 (es)
CA (2) CA3163507A1 (es)
IL (2) IL293522A (es)
MX (2) MX2022006861A (es)
WO (2) WO2021113535A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293522A (en) * 2019-12-04 2022-08-01 Scripps Research Inst Peptide conjugates and methods of use
WO2023207106A1 (zh) * 2022-04-29 2023-11-02 苏州星洲生物科技有限公司 Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
TW202410918A (zh) * 2022-05-27 2024-03-16 韓商Ｄ＆Ｄ製藥科技股份有限公司 用於治療神經病症之組合物及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006598A2 (en) * 2010-07-09 2012-01-12 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
WO2014178018A1 (en) * 2013-05-02 2014-11-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
KR102455171B1 (ko) * 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
WO2016205488A1 (en) * 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3781682A1 (en) * 2018-04-19 2021-02-24 Stichting VU Protein macrocyclization
IL293522A (en) * 2019-12-04 2022-08-01 Scripps Research Inst Peptide conjugates and methods of use

Also Published As

Publication number Publication date
US20230071371A1 (en) 2023-03-09
MX2022006861A (es) 2022-07-11
EP4069274A1 (en) 2022-10-12
KR20220123648A (ko) 2022-09-08
EP4069726A2 (en) 2022-10-12
JP2023504184A (ja) 2023-02-01
CA3163507A1 (en) 2021-06-10
JP2023513658A (ja) 2023-04-03
IL293460A (en) 2022-07-01
CA3163522A1 (en) 2021-06-10
AU2020397918A1 (en) 2022-06-23
AU2020397917A1 (en) 2022-06-23
WO2021113524A3 (en) 2021-07-15
EP4069726A4 (en) 2024-03-20
WO2021113524A2 (en) 2021-06-10
WO2021113535A1 (en) 2021-06-10
US20230057847A1 (en) 2023-02-23
IL293522A (en) 2022-08-01
EP4069274A4 (en) 2024-04-10
CN115052886A (zh) 2022-09-13
KR20220110244A (ko) 2022-08-05
CN115052615A (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
MX2022006732A (es) Conjugados peptidicos y metodos de uso.
JOP20210337A1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
WO2016172726A9 (en) Modulators of ror1-ror2 binding
EA200970810A1 (ru) Модифицированные полипептиды рецептора активина и их применение
MX2017000972A (es) Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
MY187827A (en) New polypeptide having affinity to pd-l1
EP4245775A3 (en) Multi-specific binding conjugate, related pharmaceutical compositions and use
WO2011156655A3 (en) Novel glp-1 receptor stabilizers and modulators
MX370666B (es) Novedosos moduladores del receptor de péptido tipo glucagón 1 (glp-1).
PH12021550048A1 (en) Selective estrogen receptor degraders.
CR20200487A (es) Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX2020009286A (es) Antagonistas del receptor de adenosina y usos de los mismos.
MX2021013341A (es) Formas solidas de un inhibidor de glyt1.
EP4011372A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING AFRICAN SWINE FEVER, AND USE
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
BRPI0505090A (pt) composição de toner
MX2016011115A (es) Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1.
MX2009003300A (es) Vectores de rhinovirus recombinantes.
IL285645A (en) Peptides targeting gip and glp-2 receptors for the treatment of bone disorders
PH12020500228A1 (en) Pharmacutical composition comprising remogliflozin and antidiabetic agent
MX2021005038A (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas.